Physician profile
James Chappuis
NPI 1891776159
$1,837.82
in general payments reported to CMS, 2019-2025
9 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.24 · 2020: $43.18 · 2022: $34.67 · 2024: $1,258 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1,518 · Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,517.70 |
| Food and Beverage | $208.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Restor3d, INC. | $1,517.70 | 2024-2025 | |
| Orthofix Medical, INC. | $194.38 | 2025 | Firebird Si Navigation System |
| Terumo Bct, INC. | $34.24 | 2019 | |
| Surgalign Spine Technologies, INC. | $28.86 | 2020 | |
| Spinal Elements, INC. | $19.67 | 2022 | |
| Theragen, INC. | $15.00 | 2022 | |
| Medtronic USA, INC. | $14.32 | 2020 | |
| Nevro Corp. | $13.65 | 2024 | Senza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$443,250.55 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chappuis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.